Asset Details
Do you wish to reserve the book?
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes
Do you wish to request the book?
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes
2017
Overview
KCNQ1 channel is a member of the voltage-gated potassium channel KQT-like subfamily. The KCNQ1 gene has recently been identified as a susceptibility locus for type 2 diabetes mellitus （T2DM）. In the present study, we examined the effects of KCNQ1 variants on the therapeutic response to modified-release gliclazide （gliclazide MR） treatment in Chinese patients newly diagnosed with T2DM. A total of 100 newly diagnosed T2DM patients without a history of any anti-diabetic medications were treated with gliclazide MR for 16 weeks, but 91 patients completed the entire study. The anthropometric parameters were determined at baseline and at the final visit, while clinical laboratory tests were performed at baseline and on weeks 2, 4, 6, 12, 16. Two SNPs, rs2237892 and rs2237895, in the region of the KCNQ1 gene weregenotyped in all the participants. All calculations and statistical analyses were conducted using SPSS. The rs2237892 TT homozygotes exhibited significantly higher 2-h glucose levels at baseline （P〈0.05） and a lower cumulative attainment rate of the target 2-h glucose level （Plog-raok=0.020） than the C allele carriers. Patients with greater numbers of rs2237892 T alleles exhibited larger augmentations （＆） in the 2-h glucose levels （P=0.027）; and patients with the rs2237892 TT genotype exhibited a higher △ homeostasis model assessment of L3-cell function （HOMA-β） than CC and CT genotype carriers （P=0.021 and P=0.043, respectively）. Moreover, the rs2237895 C allele was associated with a greater decrement in ＆ glycated hemoglobin （HbAlc） （P=0.024）; and patients with the CC genotype exhibited greater variance than those with the AA and AC genotypes （P=0.005 and 0.021, respectively）. Compared with the C allele, the odds ratio for treatment success among carriers of the rs2237892 T allele was 2.533 （P=0.007）; and the rs2237895 C allele was associated with a 2.360-fold decrease in HbAlc compared with the A allele （P=0.009）. KCNQ1 polymorphisms are associated with gliclazide MR efficacy in Chinese patients with type 2 diabetes.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Alleles
/ Biomedical and Life Sciences
/ Blood Glucose - drug effects
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - genetics
/ Female
/ Genotype
/ Gliclazide - therapeutic use
/ Glycated Hemoglobin - drug effects
/ Humans
/ KCNQ1 Potassium Channel - genetics
/ Male
/ Original
/ Polymorphism, Single Nucleotide - genetics
/ Sulfonylurea Compounds - pharmacology
/ Sulfonylurea Compounds - therapeutic use
/ Vaccine
/ 中国人
/ 反应
/ 基因型变异
/ 基因多态性
/ 患者
/ 易感基因
/ 药物治疗
